What is Leerink Partnrs’ Forecast for VYGR Q1 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo expects that the company will earn ($0.17) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and Q4 2025 earnings at ($0.17) EPS.

Several other analysts also recently weighed in on VYGR. Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wedbush assumed coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $15.97.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $5.53 on Friday. The firm has a market capitalization of $302.10 million, a price-to-earnings ratio of 7.79 and a beta of 0.93. Voyager Therapeutics has a 1-year low of $4.99 and a 1-year high of $10.66. The company has a 50-day moving average of $5.82 and a 200 day moving average of $6.67.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the prior year, the company posted ($0.59) EPS.

Insiders Place Their Bets

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH acquired a new position in Voyager Therapeutics during the 3rd quarter valued at approximately $6,192,000. Armistice Capital LLC increased its position in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares during the period. Barclays PLC raised its stake in Voyager Therapeutics by 55.8% in the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after acquiring an additional 37,398 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter worth about $216,000. Finally, Massachusetts Financial Services Co. MA grew its stake in Voyager Therapeutics by 19.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock valued at $1,005,000 after purchasing an additional 28,333 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.